US$ 28.98
dpp 4 inhibitor and glp 1 agonist Specific actions of GLP-1 receptor agonists DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes Insights into the Roles of
Description
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology

Aoki R, Kamikado K, Suda W, Takii H, Mikami Y, Suganuma N, et al

Nathan DM, Buse JB, Davidson MB, et al

Effects on adipose tissue GIPRs are abundant in adipose tissue (170)
